Who
Daniel G. Welch
Director
Company insider
Files Form 4 as: Director, Structure Therapeutics; Director, Prothena Corporation; Director, Ultragenyx Pharmaceutical; Director, Nuvation Bio; Director, Seagen; Director, Intercept Pharmaceuticals; Director, AveXis; Director, Hyperion Therapeutics.
In numbers
- Trades disclosed
- 357
- Buys
- 0
- Sells
- 40
- Bought
- $0
- Sold
- $74.7M
- Companies
- 9
- Companies where not an officer
- 8
- First trade
- 15 Mar 2006
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,453 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,453 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,751 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —14,058 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —14,058 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,751 at $0.00 | filing |
| 23 Jun 2025filed 25 Jun 2025 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,804 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —10,787 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —5,740 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,183 at $0.00 | filing |
| 25 Jun 2024filed 27 Jun 2024 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —9,900 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —5,345 at $0.00 | filing |
| 24 May 2024filed 29 May 2024 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —293,203 at $0.00 | filing |
| 24 May 2024filed 29 May 2024 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —366,744 at $0.00 | filing |
| 24 May 2024filed 29 May 2024 | NUVB Nuvation BioBiotechnology | SEC FORM 4 Code M | $510K293,203 at $1.74 | filing |
| 24 May 2024filed 29 May 2024 | NUVB Nuvation BioBiotechnology | SEC FORM 4 Code M | $601K366,744 at $1.64 | filing |
| 15 May 2024filed 17 May 2024 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.